Breast Cancer Patients with Estrogen Receptor-Negative/progesterone Receptor-Positive Tumor: Being Younger and Getting Less Benefit from Adjuvant Tamoxifen Treatment

Kaixian Yu,Gen‐Hong Di,Zhongcai Shao
DOI: https://doi.org/10.1200/jco.2008.26.15_suppl.22032
IF: 45.3
2008-01-01
Journal of Clinical Oncology
Abstract:22032 Background: Most receptor-negative/progesterone receptor-positive (ER-/PgR+) patients are premenopausal cases, with few adjuvant endocrine therapeutic alternatives but tamoxifen(TAM). The efficacy of adjuvant TAM on patients with ER-/PgR+ tumor is still controversial. In this study, we evaluated the efficacy of adjuvant TAM on patients with ER-/PgR+ tumor. Methods: Among all 1836 consecutive operable patients with primary breast cancer, 798 cases were with ER+/PgR+ tumor and 205 with ER-/PgR+ tumor. In order to investigate the differences of survivals between groups, we sub-grouped the patients according to ER/PR phenotypes and whether the patient had been treated with adjuvant TAM therapy. Results: Patients with ER-/PgR+ tumor were younger than those with ER+/PgR+ tumor (P=0.021), and were mainly premenopausal (P=0.013). ER-/PgR+ patients were related to more involved lymph nodes and later stage. In the absence of TAM treatment, ER+/PgR+ group had a similar survival to ER-/PgR+ group in terms of 5-year DFS, as well as OS. After TAM treatment, both groups had increased survival rates comparing with the baseline of non-TAM-treated groups. In addition, significant survival differences were observed between the TAM-treated ER+/PgR+ group and ER-/PgR+ group either in DFS (P=0.016) or OS (P=0.007). Of the TAM-treated patients, by sub-dividing the chemotherapy-treated population into CMF group and CA(E)F group, we found that ER-/PgR+ group got more benefits from CMF regimen than from CA(E)F. STEPP analysis showed that the ER-/PgR+ group had an obvious worse survival in younger patients (younger than 55 ys) than ER+/PgR+ group. Axillary lymph nodes involvement was unique independent prognostic factor for ER-/PgR+ group. Conclusions: Patients with ER-/PgR+ tumor are mainly premenopausal and young. Although patients with ER-/PgR+ tumor are generally considered as candidates for endocrine therapy clinically, they gain less benefit from adjuvant TAM treatment than ER+/PgR+ group. No significant financial relationships to disclose.
What problem does this paper attempt to address?